Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- ZUMZ +14.8%, (reports earnings and Aug comparable sales increased 7.4%),AGX +11.8%, BV +8.4%, CLDR +3.7%, RDFN +3.3%, OKTA +3.2%, REVG +2.4%
Select Cyber security names related names showing strength:
- SYMC +2.5%, FEYE +2%, CHKP +1.5%, CYBR +1%, HACK +0.6%, PANW +0.5%
Other news:
- KURA +26.3% (announces its Phase 2 trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck met its primary endpoint)
- OPGN +8.3% (presents results on the Acuitas AMR Gene Panel u5.47 at the 2017 ASM/ESCMID Conference)
- AVEO +6% (continued strength)
- CLVS +4% (ARIEL3 study successfully achieved its primary endpoint)
- IDRA +2% (reports pre-clinical data from its ongoing intratumoral IMO-2125 development program)
- STM +1.7% (Euronext announces annual review results on the CAC family indices -- to include STMicroelectronics in the CAC 40, exclude Nokia (NOK))
- SNY +0.5% (Sanofi and Regeneron (REGN) receive FDA Breakthrough Therapy Designation for Cemiplimab)
Analyst comments:
- TTWO +1% (initiated with a Buy at Goldman)
- EA +0.8% (initiated on the Conviction Buy List at Goldman)